The HealthShares Neuroscience ETF (Ticker: HHN) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares Neuroscience Index. The index is comprised of companies engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Companies were equal weighted at the fund's inception, then allowed to float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.
